You are here: Industry Insights > cabozantinib

News List

Two new developments in kidney cancer treatments europeanpharmaceuticalreview
February 19, 2021
Studies suggest there are better treatment options than sunitinib for kidney cancers; cabozantinib in metastatic papillary kidney cancer and lenvatinib/pembrolizumab for renal cell carcinoma.
FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma americanpharmaceuticalreview
January 28, 2021
The U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo, Bristol-Myers Squibb) and cabozantinib (Cabometyx, Exelixis) as first-line treatment for patients with advanced renal cell carcinoma (RCC).
Cabozantinib reduces tumour burden in Phase II neurofibromatosis trial europeanpharmaceuticalreview
January 18, 2021
Forty percent of neurofibromatosis type 1 patients enrolled in the trial had a >20 percent reduction in tumour burden with cabozantinib.
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer pharmaceutical-business-review
July 06, 2020
Exelixis, Inc. announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) in patients with metastatic castration-resistant prostate cancer (CRPC) who have been ...
Cabozantinib shows promise as first line treatment for differentiated thyroid cancer europeanpharmaceuticalreview
May 05, 2019
A kinase inhibitor called cabozantinib could be a viable therapy option for patients with metastatic, radioactive iodine-resistant thyroid cancer…
FDA Approves Cabozantinib for Hepatocellular Carcinoma americanpharmaceuticalreview
January 17, 2019
On January 14, 2019, the Food and Drug Administration (FDA) approved cabozantinib (CABOMETYX, Exelixis) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib....
Ipsen's Cabometyx gains European approval in hepatocellular carcinoma pharmafile
November 19, 2018
Ipsen’s Cabometyx has received approval from the European Commission for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma
Ipsen’s Cabometyx wins EU nod for liver cancer pharmatimes
November 19, 2018
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
NICE recommends cabozantinib for advanced renal cell cancer europeanpharmaceuticalreview
July 11, 2017
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending cabozantinib for some kidney cancer patients